Alzheimer's

Five things for pharma marketers to know: Tuesday, February 21, 2017

Five things for pharma marketers to know: Tuesday, February 21, 2017

By By

Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Friday, December 9, 2016

Five things for pharma marketers to know: Friday, December 9, 2016

By

BMS to pay $19.5 million to settle marketing violations for Abilify; AstraZeneca to cut 700 U.S. jobs; Trump reportedly considering Jim O'Neill to lead FDA

Five things for pharma marketers to know: Wednesday, November 23, 2016

Five things for pharma marketers to know: Wednesday, November 23, 2016

By

Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China

Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

By

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

Five things for pharma marketers to know: Wednesday, December 23, 2015

Five things for pharma marketers to know: Wednesday, December 23, 2015

By

Clinton calls for Alzheimer's funding; an FDA approval of an older drug may mean higher prices; the FDA approves AstraZeneca's gout drug

Five things for pharma marketers to know: Tuesday, December 22, 2015

Five things for pharma marketers to know: Tuesday, December 22, 2015

By

Valeant says it lost few reps despite business scrutiny; Novartis CEO says drugmakers must share benefits of new medicines with other healthcare stakeholders; Bloomberg analysis finds US pays more for branded drugs after discounts

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

By

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

By

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

Actavis case may not serve as Namenda precedent

A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.

Pfizer teams up with Alzheimer's foundation

Pfizer's academic research arm will work together with the Alzheimer's Drug Discovery Foundation to jointly invest in scientific research to identify clinical candidates for testing.

J&J inks Alzheimer's vaccine deal

The $509-million agreement gives J&J rights to AC Immune's experimental anti-Tau vaccine.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

By By

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

Alzheimer's study to use healthy patients

Novartis and the nonprofit Banner Alzheimer's Institutes are testing a theory that treating healthy patients could prevent or delay Alzheimer's disease.

Study links Actos with delayed dementia

German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.

Study finds Alzheimer's misunderstood

Study finds Alzheimer's misunderstood

By

An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.

Games may not improve memory

The NYT reports that the data on gaming long-term memory is inconclusive.

Alzheimer's bigger cause of death than thought

Researchers say death certificates erroneously account for only the immediate cause of death, leading to a poor accounting of deaths caused by the memory-robbing disease.

Biogen, Eisai in Alzheimer's pact

Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

Lundbeck, Otsuka collborate on Alzheimer's

Vaccine LU AF20513 is the their third Alzheimer's collaboration.

Eleven genes linked to Alzheimer's

The NIH says the insight could inspire new ways to tackle the brain-destroying disease.

Can we handle cost of a healthy, aging population?

Can we handle cost of a healthy, aging population?

By

The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.

Business briefs: Sanofi, Alzheimer's, and healthcare reform news

By

Sanofi has to provide more Aubagio data to the UK's NICE; healthcare reform's sixes and sevens; NIH puts money toward Alzheimer's research

Study shoots down AD drug class in mild patients

By

Researches say cognitive enhancers, a group which includes drugs like Aricept and Exelon, fail to slow decline in patients with Alzheimer's over the long term.

Business briefs: inVentiv, Novo, Bayer, Purdue

inVentiv launches new policy shop; early test shows Novo's Victoza may have Alzheimer's future; Bayer joins the list of China's scrutinized pharma companies; a Chicago bar gives Purdue unwanted attention

Business briefs: Takeda, Sangamo, Catalyst, plus seniors and insurance

Takeda moves an Alzheimer's treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance

"Sensor you swallow" passes psych test

"Sensor you swallow" passes psych test

By

Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.

Elan's beyond-the-plaque Alzheimer's med gets fast-tracked

By

Elan's strategy: focus on agitation and aggression associated with the disease.

Business briefs: Lundbeck/Otsuka, Abbott, Merck

Lundbeck and Otsuka prime Alzheimer's med for Phase III trials; Abbott reports Q2 results; and an FDA panel shrugs off Merck's muscle relaxant for another day.

OPINION

Why President Trump Won't Overhaul the FDA

Newsletters